# Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score

Source: https://onco.cc/key-papers/paper-van-neste-urinary-biomarker-prostate-eur-urol-2016/  
OnCo record `paper-van-neste-urinary-biomarker-prostate-eur-urol-2016` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The validation of a urine test reading two genes, combined with clinical factors, to detect high-grade prostate cancer.

## Summary

The multimodal approach reached an overall area under the curve of 0.90 (95% CI 0.85 to 0.95) in the validation cohort.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: European Urology
- Year: 2016
- DOI: 10.1016/j.eururo.2016.04.012
- Authors: Van Neste L, Hendriks RJ, Dijkstra S, et al.
- Findings: Area under the curve 0.90 in validation.
- What it means: Urine mRNA plus clinical factors separates high-grade from low-grade or no cancer.
- Caveats: Urine taken after a rectal examination.

## Sources

- Van Neste et al., Eur Urol 2016: https://doi.org/10.1016/j.eururo.2016.04.012
- PubMed: https://pubmed.ncbi.nlm.nih.gov/27108162/

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Liquid RNA biopsy (cell-free, vesicle and platelet RNA)](https://onco.cc/technologies/liquid-rna-biopsy/)
- drugs: [SelectMDx](https://onco.cc/drugs/selectmdx/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-van-neste-urinary-biomarker-prostate-eur-urol-2016.json